HER2-low expression seems to increase with ER expression and appears to be enriched in the advanced setting [91]; indeed, HER2 expression is dynamic and can change during disease progression with up to 40% discordance between primary and metastatic tumors [94,95]. This evidence concerns the gene ERBB2 and metastatic neoplasm.